Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

Table 2 Comparison between the patient group (pre-TMS) and control group as regards neurokinin A serum level, and comparison between pre-TMS and post-TMS treatment neurokinin A serum level in the patient group

Neurokinin A serum level		Control group, no. = 20	Patient group, no. = 40	Test value^•	P value
Pre-TMS	Mean ± SD	1.15 ± 0.28*	24.11 ± 2.26	− 45.131	< 0.001
Pre-TMS	Range	0.51–1.85	19.38–27.93	− 45.131	< 0.001
Post-TMS in patient group	Mean ± SD	1.15 ± 0.28*	12.60 ± 3.08	− 16.524	< 0.001
Post-TMS in patient group	Range	0.51–1.85	9.32–25.45	− 16.524	< 0.001
Paired t test			− 5.511
P value			< 0.001 (HS)

P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.01, highly significant (HS)
^•Independent t test
*Neurokinin A serum level was calculated in the control group one time used in the comparison with the patient group serum level pre-TMS and post-TMS